Novotech Releases Report on Current State of Triple-Negative Breast Cancer Clinical Trials
Key biomarkers and cutting-edge treatments, such as PARP inhibitors and immunotherapy combinations, drive advancements in TNBC outcomes SYDNEY–(BUSINESS WIRE)– Novotech, the leading global full-service clinical...